Old Web
English
Sign In
Acemap
>
authorDetail
>
Dennis Brinker
Dennis Brinker
Eli Lilly and Company
Medicine
Atopic dermatitis
Baricitinib
Internal medicine
Randomized controlled trial
8
Papers
117
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
25977 Selected infection topics in adult patients with moderate-to-severe atopic dermatitis treated with baricitinib
2021
Journal of The American Academy of Dermatology
Melinda Gooderham
Jamie Weisman
Orin Goldblum
Dennis Brinker
Maher Issa
Kristian Reich
Show All
Source
Cite
Save
Citations (1)
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
2021
American Journal of Clinical Dermatology
Brett A. King
Catherine Maari
Edward Lain
Jonathan I. Silverberg
Maher Issa
Katrin Holzwarth
Dennis Brinker
Tracy E. Cardillo
Fabio P. Nunes
Eric L. Simpson
Show All
Source
Cite
Save
Citations (5)
Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: an updated integrated safety analysis
2020
Mark C. Genovese
Josef S. Smolen
Tsutomu Takeuchi
Gerd R. Burmester
Dennis Brinker
Terence P Rooney
Jinglin Zhong
Mo Daojun
Chadi Saifan
Anabela Cardoso
M Issa
Wen Shuo Wu
Kevin L. Winthrop
Show All
Source
Cite
Save
Citations (23)
THU0078 SAFETY PROFILE OF BARICITINIB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS UP TO 7 YEARS: AN UPDATED INTEGRATED SAFETY ANALYSIS
2019
Annals of the Rheumatic Diseases
Mark C. Genovese
Josef S. Smolen
Tsutomu Takeuchi
Gerd R. Burmester
Dennis Brinker
Terence Rooney
Jinglin Zhong
Daojun Mo
Chadi Saifan
Anabela Cardoso
M Issa
Wen Shuo Wu
Kevin L. Winthrop
Show All
Source
Cite
Save
Citations (23)
1